Keros Therapeutics (KROS) Operating Income Growth (5y) (2024 - 2025)

Keros Therapeutics (KROS) Operating Income Growth (5y) (2024 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 65,538.84 Bn 65,538.56 Bn -
2 Nanobiotix 1,912.79 Bn 1,912.72 Bn -
3 Akari Therapeutics 1,009.43 Bn 1,009.43 Bn -
4 BeOne Medicines 469.46 Bn 464.67 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.69 Bn 115.45 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.41 Bn 61.65 Bn 3.31 Bn
7 Belite Bio 62.84 Bn 62.84 Bn -
8 Argenx Se 56.10 Bn 50.91 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.48 Bn 34.47 Bn 959.66 Mn
10 Keros Therapeutics 382.63 Mn 95.23 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 -17.10%
Sep 30, 2025 -5.19%
Jun 30, 2025 -29.54%
Mar 31, 2025 75.13%
Dec 31, 2024 -81.18%
Sep 30, 2024 -90.70%
Jun 30, 2024 -80.25%
Mar 31, 2024 -76.16%